Skip to main content

Market Overview

Seelos Therapeutics' SLS-002 Shows Clinically Meaningful Efficacy As Anti-Depressive, Anti-Suicidal Therapeutic After Single Dose

Share:
Seelos Therapeutics' SLS-002 Shows Clinically Meaningful Efficacy As Anti-Depressive, Anti-Suicidal Therapeutic After Single Dose
  • Seelos Therapeutics Inc (NASDAQ: SEELhas announced data from Part 1, the open-label cohort, of its Proof-of-Concept study of SLS-002 for acute suicidal ideation and behavior in patients with Major Depressive Disorder.
  • On depression scale, 76.5% response rate on Day 1 (n=17), 92.9% response rate on Day 16 (n=14) and 100% response rate on Day 29 (n=13) was observed.
  • 35.3% remission rate on Day 1, 78.6 % remission rate on Day 16, and 76.9% remission rate on day 29.
  • 94% of subjects had more than 14 points within-patient change on the suicidality tracking scale from their baseline and one subject = 4 points within-patient change on Day 1.
  • SLS-002 was well tolerated, with 47% of subjects having at least one treatment-emergent adverse event.
  • No serious adverse events were observed, and all adverse events were mild or moderate, mostly transient in nature, and with no new or unique safety signals identified.
  • Price Action: SEEL shares are trading 17% lower at $4.31 during the premarket session on the last check Monday.
 

Related Articles (SEEL)

View Comments and Join the Discussion!

Posted-In: antidepressants BriefsBiotech News Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com